Wealthspire Advisors (Maryland)’s Sciclone Pharmaceuticals Inc SCLN Stock Holding History

Wealthspire Advisors (Maryland)’s Portfolio SCLN Stock Details SCLN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q4	–	Sell	-9	Closed	–	–	2655
2017 Q3	$0	Buy	+9	New	+$99	﹤0.01%	2616

Wealthspire Advisors (Maryland)'s SCLN Position: Q4 2017 in Review

Wealthspire Advisors (Maryland) sold out of Sciclone Pharmaceuticals Inc (SCLN) in Q4 2017, closing a stake of 9 shares.

Wealthspire Advisors (Maryland) first reported a position in SCLN in Q3 2017 and held it in 1 quarter. The position peaked at $0 in Q3 2017. 0 funds tracked by Wall St. Rank hold SCLN as of Q4 2017.

Wealthspire Advisors (Maryland) reported no remaining Sciclone Pharmaceuticals Inc position as of Q4 2017 after selling out during the quarter.
Wealthspire Advisors (Maryland) sold 9 Sciclone Pharmaceuticals Inc shares in Q4 2017.
Wealthspire Advisors (Maryland) first reported a position in Sciclone Pharmaceuticals Inc in Q3 2017 and held it in 1 quarter.
Wealthspire Advisors (Maryland)'s Sciclone Pharmaceuticals Inc position peaked at $0 in Q3 2017.
0 funds tracked by Wall St. Rank held Sciclone Pharmaceuticals Inc as of Q4 2017.

Based on Wealthspire Advisors (Maryland)'s 13F filing for Q4 2017, filed 7 Feb 2018.